9/21/2020  9:26:03 AM Chg. -0.050 Volume Bid9:26:12 AM Ask9:26:12 AM Market Capitalization Dividend Y. P/E Ratio
2.360EUR -2.07% 9,365
Turnover: 22,418.700
2.360Bid Size: 179 2.440Ask Size: 1,104 154.09 mill.EUR 0.00% -

Business description

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The Company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon®, is a blood-based screening test for the early detection of colorectal cancer. Epi proColon® is currently marketed in Europe and China.
 

Management board & Supervisory board

CEO
Gregory Hamilton
Management board
Albert Weber, Dr. Jorge Garces
Supervisory board
Heino von Prondzynski, Alexander Link, Dr. Ann Clare Kessler, Dr. Helge Lubenow, Franz Thomas Walt, Prof. Dr. Günther Reiter
 

Company data

Name: Epigenomics AG
Address: Geneststraße 5,D-10829 Berlin
Phone: +49-30-24345-0
Fax: +49-30-24345-555
E-mail: contact@epigenomics.com
Internet: www.epigenomics.de
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 54.03%
IPO date: 7/19/2004

Investor relations

Name: Frederic Hilke
IR phone: +49-221-9140-9719
IR Fax: -
IR e-mail: ir@epigenomics.com

Company calendar

CW 46 | 11/12/2020 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
54.03%
Deutsche Balaton AG
 
16.22%
Morgan Stanley
 
9.74%
Bridger Healthcare Ltd.
 
9.66%
Altium Growth Fund, LP
 
5.19%
683 Capital Management, LLC
 
5.16%